Literature DB >> 23839224

Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line.

Kelsie Gillies1, Jaime Wertman, Nicholle Charette, Denis J Dupré.   

Abstract

BACKGROUND: Most prostate cancer-related deaths result from metastasis. CXCR4 and CCR2 are known to govern cellular processes resulting in cell migration, proliferation and survival. These receptors are expressed at low levels on normal prostate cells and are highly expressed on malignant and metastatic prostate cancer cells. Signaling of these receptors is relatively well understood, but processes governing their expression at the cell membrane are not. PC3 prostate cancer cells were used to demonstrate the importance of various Rab GTPases on cell surface expression and signaling of CXCR4 and CCR2, along with the CXCR4/CCR2 heterodimer.
METHODS: PC3 prostate cancer cells were transfected with select Rab GTPase wild-type and dominant negative constructs. Effects of each Rab GTPase on endogenous cell surface expression of the individual receptors, along with the overexpressed CXCR4/CCR2 heterodimer, were determined by biotin-streptavidin cell surface assays. These results were corroborated by assessing signal transduction, measured by focal adhesion kinase (FAK) activation.
CONCLUSION: Rab GTPases required for cell surface expression and signal transduction of CXCR4 or CCR2 differ from those required for the CXCR4/CCR2 heterodimer. Determining trafficking regulators of two key receptors involved in the metastatic transition may identify new targets to restrict expression of chemokine receptors employed during metastasis.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839224     DOI: 10.1159/000350126

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

1.  CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer.

Authors:  Ying Gao; Chunyu Li; Min Nie; Yao Lu; Shunsen Lin; Peng Yuan; Xun Sun
Journal:  Tumour Biol       Date:  2014-01-07

2.  Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation.

Authors:  Hui Guo; Yuemin Xu; Qiang Fu
Journal:  Tumour Biol       Date:  2015-06-02

Review 3.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

4.  Pituitary tumor-transforming gene 1 regulates invasion of prostate cancer cells through MMP13.

Authors:  Yun-Hua Lin; Yong Tian; Jun-Sheng Wang; Yong-Guang Jiang; Yong Luo; Ya-Tong Chen
Journal:  Tumour Biol       Date:  2015-07-23

5.  VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin.

Authors:  Feng Liu; Jihong Wang; Qiang Fu; Xinru Zhang; Ying Wang; Jialin Liu; Jianwen Huang; Xiangguo Lv
Journal:  Tumour Biol       Date:  2015-11-13

6.  Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/RhoA-mediated Migration.

Authors:  Kisha A Scarlett; El-Shaddai Z White; Christopher J Coke; Jada R Carter; Latoya K Bryant; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2018-01-12       Impact factor: 5.852

7.  Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Authors:  Nitin Patel; Tatsuo Itakura; Shinwu Jeong; Chun-Peng Liao; Pradip Roy-Burman; Ebrahim Zandi; Susan Groshen; Jacek Pinski; Gerhard A Coetzee; Mitchell E Gross; M Elizabeth Fini
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

8.  The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1.

Authors:  Haihua Wu; Yueyue Wang; Tiantian Chen; Yu Li; Haifeng Wang; Lingyu Zhang; Sulian Chen; Wenrui Wang; Qingling Yang; Changjie Chen
Journal:  Biosci Rep       Date:  2018-10-17       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.